The 13C-caffeine breath test detects significant fibrosis in patients with nonalcoholic steatohepatitis

Journal of Clinical Gastroenterology

Volumn 42, Issue 4, 2008, Pages 408-412

  Schmilovitz Weiss, Hemda ^a,b   Niv, Yaron ^c   Pappo, Orit ^c   Halpern, Marisa ^c   Sulkes, Jacklin ^d   Braun, Marius ^a   Barak, Nir ^a   Rotman, Yaron ^a   Cohen, Maya ^e,f   Waked, Amal ^c   Tur Kaspa, Ran ^a   Ben Ari, Ziv ^a,e  

^a Liver Institute   (Israel)

^b Gastroenterology Unit   (Israel)

^c Beilinson and Hasharon Golda Campuses ^*  (Israel)

^d Epidemiology Unit   (Israel)

^e RABIN MEDICAL CENTER   (Israel)

^f TEL AVIV UNIVERSITY   (Israel)

Author keywords

Caffeine breath test; Hepatic fibrosis; Steatohepatitis

Indexed keywords

CAFFEINE; CARBON 13;

ADULT; AGED; ARTICLE; BILIRUBIN BLOOD LEVEL; BREATH ANALYSIS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LABORATORY TEST; LIVER BIOPSY; LIVER FIBROSIS; MALE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; THROMBOCYTE COUNT;

BREATH TESTS; CAFFEINE; CARBON ISOTOPES; DIAGNOSIS, DIFFERENTIAL; FATTY LIVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 41349107251     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e318046ea65     Document Type: Article

References (31)

1. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43:S99-S112.
2. Haque M, Sanyal AJ. The metabolic abnormalities associated with non- alcoholic fatty liver disease. Best Pract Res Clin Gastroenterol. 2002;16:709-731.
3. Smedile A, Bugianesi E. Steatosis and hepatocellular carcinoma risk. Eur Rev Med Pharmacol Sci. 2005;9:291-293.
4. Ramesh S, Sanyal AJ. Evaluation and management of non-alcoholic steatohepatitis. J Hepatol. 2005;42:S2-S12.
5. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology. 2000;32:477-481.
6. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 2003;38:1449-1457.
7. Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variations in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 2002;97:2614-2618.
8. Pasha T, Gabriel S, Therneau T, et al. Cost- effectiveness of ultrasound-guided liver biopsy. Hepatology. 1998;27:1220-1226.
9. Poniachik J, Bernstein DE, Reddy KR, et al. The role of laparoscopy in the diagnosis of cirrhosis. Gastrointest Endosc. 1996;43:568-571.
10. Maharaj B, Maharaj RJ, Leary WP, et al. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet. 1986;1:523-525.
11. Arnaud MJ, Welsch C. Theophylline and caffeine metabolism in man. In: Rietbock N, Woodcock BG, Staib AH, eds. Theophylline and other Methylxanthines. Braunschweig/Wiesbaden, Germany: Vieweg and Son; 1981:135-148.
12. Bonati M, Latini R, Galletti F, et al. Caffeine disposition after oral doses. Clin Pharmacol Ther. 1982;32:98-106.
13. Blanchard J, Sawers SJ. The absolute bioavailability of caffeine in man. Eur J Clin Pharmacol. 1983;24:93-98.
14. Sanyal AJ. Mechanisms of disease: pathogenesis of nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol. 2005;2:46-53.
15. 13C-caffeine breath test as a noninvasive, quantitative test of liver function. Hepatology. 2003;38:1227-1236.
16. Minuk H. Diabetes mellitus: new guidelines. J Insur Med. 2000;32:269-270.
17. Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology. 2002;123:1705-1725.
18. Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467-2474.
19. Lambert GH, Kotake AN, Schoeller D. The CO2 breath tests as monitors of the cytochrome P450 dependent mixed function monooxygenase system. Prog Clin Biol Res. 1983;135:119-145.
20. 13C-methacetin. Eur J Nucl Med. 1985;10:129-133.
21. Lara Baruque S, Razquin M, Jimenez I, et al. 13C-phenylalanine and 13C-methacetin breath test to evaluate functional capacity of hepatocyte in chronic liver disease. Dig Liver Dis. 2000;32:226-232.
22. 13C-methacetin breath test as liver function test in patients with chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2005;21:179-185.
23. 13C-caffeine breath test distinguishes significant fibrosis in chronic hepatitis B and reflects response to lamivudine therapy. Aliment Pharmacol Ther. 2005;22:395-403.
24. Abernethy DR, Todd EL, Schwartz JB. Caffeine disposition in obesity. Br J Clin Pharmacol. 1985l;20:61-66.
25. Caraco Y, Zylber-Katz E, Berry EM, et al. Caffeine pharmacokinetics in obesity and following significant weight reduction. Int J Obes Relat Metab Disord. 1995;19:234-239.
26. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115:209-218.
27. Forns X, Ampurdanes S, Llovet JM, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology. 2002;36:986-992.
28. Wai CT, Greenson JK, Fontana RJ, et al. A simple non-invasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518-526.
29. Imbert-Bismut F, Ratziu V, Pieroni L, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet. 2001;357:1069-1075.
30. 2 breath tests: methodology and fundamental considerations. J Lab Clin Med. 1977;90:412-421.
31. 13C- urea breath test for Helicobacter pylori infection: stability of samples over time. Scand J Gastroenterol. 1999;34:942-943.